YolTech Gene Editing Trial Shows Promise for One-Time AATD Cure

SHANGHAI – February 19, 2026 – YolTech Therapeutics has unveiled promising interim results for a novel gene editing therapy that could represent a turning point for individuals with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder that can cause severe lung and liver disease. The company announced that its investigational therapy, YOLT-202, was well-tolerated and successfully restored protective protein levels in the first patients treated in a clinical study.

The data, from an investigator-initiated trial, marks a significant milestone for the field of in vivo base editing—a precise form of gene therapy designed to correct faulty genes directly inside the body. For the thousands affected by AATD, this news offers a glimpse of a potential one-time, permanent treatment, a stark contrast to the lifelong management required today.

A Potential Paradigm Shift in AATD Treatment

AATD is caused by mutations in the SERPINA1 gene, which provides instructions for making the alpha-1 antitrypsin protein. The most severe form is caused by the PiZZ genotype, where misshapen AAT protein gets trapped in the liver, leading to liver damage, and fails to reach the lungs, leaving them vulnerable to damage.

YOLT-202 is designed to correct this fundamental problem. Using a proprietary adenine base editor delivered via lipid nanoparticles (LNPs), the therapy directly edits the mutated DNA in liver cells, correcting the 'Z' mutation to the normal 'M' version. This allows the body to produce its own functional AAT protein.

The first-in-human study (NCT07193615) evaluated single intravenous doses of YOLT-202 in adult AATD patients with the PiZZ genotype. The interim results from the first two participants are striking:

• Rapid and Robust Response: Both patients, dosed at 35 mg and 45 mg respectively, showed rapid and dose-dependent increases in functional AAT protein levels as early as one week after infusion.
• Restoration of Protective Levels: AAT levels in both patients surpassed the 11 μM threshold considered necessary to protect the lungs. Critically, the patient in the higher 45 mg dose group saw their AAT levels rise into the normal range (above 20 μM).
• High-Quality Correction: The newly produced AAT protein was structurally and functionally normal. In the 45 mg dose group, over 95% of the AAT protein was the corrected, healthy M-type.
• Favorable Safety: The therapy was well-tolerated, with no serious adverse events reported. The most common side effect was a mild, manageable infusion-related reaction. Observed elevations in liver enzymes were temporary and resolved without intervention.

“These interim findings mark an exciting and important milestone for YolTech and for patients living with severe AATD,” stated Yuxuan Wu, M.D., Founder and CEO of YolTech Therapeutics, in the company's press release. “The rapid, robust, and dose‑dependent increases in functional AAT levels observed in this study—particularly among individuals with the PiZZ genotype—underscore the transformative potential of in vivo base editing as a one‑time treatment approach.”

Redefining the Competitive Landscape

The current standard of care for AATD-related lung disease is augmentation therapy—weekly intravenous infusions of AAT protein derived from donated plasma. While it can slow lung deterioration, it is a costly, burdensome, lifelong treatment that does not address the underlying genetic cause or prevent the associated liver disease. A one-time therapy like YOLT-202 could eliminate this burden entirely.

YolTech is not alone in the race to revolutionize AATD treatment. The field is a hotbed of innovation, with several companies pursuing advanced genetic medicines:

• RNA-based therapies, such as Arrowhead Pharmaceuticals' fazirsiran, aim to reduce the production of the toxic Z-protein in the liver, primarily targeting liver disease. Wave Life Sciences' WVE-006 is an RNA editing therapy designed to fix the genetic error at the messenger RNA level, which may require repeat dosing.
• Direct gene editing competition comes from companies like Beam Therapeutics, whose BEAM-302 also uses an LNP-delivered base editor to correct the PiZ mutation and is currently in Phase 1/2 trials.

YolTech's positive data places it firmly at the forefront of this competitive landscape. The company's proprietary HEPDONE™ platform, which uses AI and high-throughput screening to develop highly precise editors, is central to its strategy of minimizing off-target effects—a key safety concern for all gene editing technologies.

Addressing a Significant Unmet Need

While AATD is classified as a rare disease, it is significantly underdiagnosed. An estimated 235,000 people worldwide have the severe PiZZ genotype, but only a fraction have been identified. Many are misdiagnosed with chronic obstructive pulmonary disease (COPD) or asthma. This diagnostic gap highlights a vast unmet need.

The global market for AATD therapies, valued at over $800 million in 2023, is projected to grow exponentially, with some analysts forecasting it to exceed $9 billion by the early 2030s. This growth is fueled by increasing awareness, better diagnostic tools, and the promise of transformative therapies like YOLT-202.

For patients, the prospect of a single-dose treatment that could halt both lung and liver disease progression is life-changing. It would mean freedom from weekly infusions, a halt to the relentless damage caused by the disease, and the possibility of a normal life expectancy.

Navigating the Path to Approval

With this encouraging early data, YolTech is now preparing to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate global clinical trials. This is a critical step in moving YOLT-202 from a promising concept to an accessible medicine.

The therapy has already been granted Orphan Drug Designation by the FDA, a status that provides significant incentives for developing treatments for rare diseases. These benefits include tax credits, waived user fees, and, most importantly, seven years of market exclusivity upon approval.

This designation, combined with the strength of the interim data, could pave the way for an expedited regulatory review process. As YolTech prepares to expand its clinical trial to include more patients and higher dose levels, the medical community and patients alike will be watching closely, hopeful that this innovative approach to gene editing will deliver on its profound potential.